[Effect of Soluvit on stress reaction and leucocyte function in serious burn patients in shock stage].
OBJECTIVE
To investigate the effect of Soluvit on stress reaction and leucocyte function in serious burn patients in shock stage.


METHODS
Eighty-seven serious burn patients, who did not undergo operation, were divided into Soluvit treatment group and control group randomly. Patients in Soluvit treatment group were treated with two bottles of Soluvit everyday from postburn 1 st to 14 th day. Patients in control group were given 500 ml normal saline infusion instead. Blood samples were collected for determination of cortisol and malondialdehyde every 4 hours on postburn 1 st day. Leucocyte were isolated for testing chemotaxis distance and phagocytic power on postburn 7 th and 14 th day respectively.


RESULTS
The serum cortisol contents in serious burn patients were significantly elevated at 2-4 hours after treatment in Soluvit treatment and control groups. Serum cortisol and malondialdehyde levels were higher than normal values in all serious burn patients in shock stage at 10-12 hours after treatment. But the changes of serum cortisol and malondialdehyde in Soluvit treatment group were all lower than those in control group at 10-48 and 14-48 hours after treatment, respectively (all P<0.05). Leucocyte chemotaxis distance in Soluvit treatment group was longer than that in control group on both postburn 7 th and 14 th day (P<0.05 and P<0.01). In contrast, there were no significant differences in phagocytic power between two groups (both P>0.05).


CONCLUSIONS
Above results suggest that Soluvit can mitigate stress reaction and lipid peroxidation action, but enhance leucocyte chemotaxis function in severe burn patients.
Zhang
Tao
T
Department of Burn Injury, Guangzhou First Municipal People's Hospital, Guangzhou 510180, Guangdong, China. zhangtao209@yahoo.com.cn
Rong
Xin-Zhou
XZ
Yang
Rong-Hua
RH
Hua
Rong
R
Huang
Xiao-Hua
XH
Li
Qing-Hui
QH
D000293:Adolescent; D000328:Adult; D000368:Aged; D002056:Burns / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects; D012774:Shock, Traumatic / Q000097:blood / Q000209:etiology / Q000276:immunology*; D014815:Vitamins / Q000494:pharmacology*; D055815:Young Adult
D014815:Vitamins; D008315:Malondialdehyde; D006854:Hydrocortisone